par Muralidharan, Charanya;Huang, Fei;Enriquez, Jacob J.R.;Wang, Jiayi J.E.;Nelson, Jennifer J.B.;Nargis, Titli;May, Sarah S.C.;Chakraborty, Advaita;Figatner, Kayla K.T.;Navitskaya, Svetlana;Anderson, Cara C.M.;Calvo, Veronica;Surguladze, David;Mulvihill, Mark M.J.;Yi, Xiaoyan 
;Sarkar, Soumyadeep;Oakes, Scott S.A.;Webb-Robertson, Bobbie Jo B.J.M.;Sims, Emily EK;Staschke, Kirk K.A.;Eizirik, Decio L. ;Nakayasu, Ernesto Satoshi;Stokes, Michael M.E.;Tersey, Sarah SA;Mirmira, Raghavendra R.G.
Référence The Journal of clinical investigation, 134, 12
Publication Publié, 2024-06
;Sarkar, Soumyadeep;Oakes, Scott S.A.;Webb-Robertson, Bobbie Jo B.J.M.;Sims, Emily EK;Staschke, Kirk K.A.;Eizirik, Decio L. ;Nakayasu, Ernesto Satoshi;Stokes, Michael M.E.;Tersey, Sarah SA;Mirmira, Raghavendra R.G.Référence The Journal of clinical investigation, 134, 12
Publication Publié, 2024-06
Article révisé par les pairs
| Résumé : | Disclosures: VC, MES, DS, and MJM are employees of HiberCell, Inc. SAT, RGM, and HiberCell have filed a provisional patent on compounds to inhibit PERK in type 1 diabetes. SAT and RGM received an investigator-initiated award from HiberCell, Inc. for use of PERK inhibitors in this study. KAS is a consultant for and has received research support from HiberCell, Inc. SAO is a co-founder, equity holder, and consultant for OptiKIRA, LLC. |
